61 Biggest Movers From Yesterday
Gainers
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company signed an agreement with Waas Group for the development 1,040 ART systems in Spain and Portugal.
Axcella To Test NASH Candidate In Long COVID Patients
Axcella Health Inc (NASDAQ:AXLA) has announced a new clinical program investigating AXA1125 as a potential treatment for patients with Long COVID.…
Noble Capital Markets Initiates Coverage On Axcella Health with Outperform Rating, Announces Price Target of $6
Noble Capital Markets analyst Robert LeBoyer initiates coverage on Axcella Health (NASDAQ:AXLA) with a Outperform rating and announces Price Target of $6.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
From BZ’s Small Cap Healthcare Conference: Axcella Health President & CEO, Bill Hinshaw Begins Speaking
Click To Tune In Here... https://www.youtube.com/watch?v=TG5SSZDlpBo
Axcella’s Leading Drug Candidate for Overt Hepatic Encephalopathy Offers Hope in a Market Requiring Innovation
Image by Ousa Chea on Unsplash
Goldman Sachs Downgrades Axcella Health to Neutral, Lowers Price Target to $5
Goldman Sachs analyst Paul Choi downgrades Axcella Health (NASDAQ:AXLA) from Buy to Neutral and lowers the price target from $9 to $5.
Axcella’s First-of-Its-Kind NASH Treatment Shows Promising Early Results in Human Trials
Image Provided By Pixabay